Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

doi:10.1093/cid/ciu697

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Dec 2014

Svarovskaia Evguenia S, Dvory-Sobol Hadas, Parkin Neil, Hebner Christy, Gontcharova Viktoria, Martin Ross, Ouyang Wen, Han Bin, Xu Simin, Ku Karin, Chiu Sophia, Gane Edward, Jacobson Ira M, Nelson David R, Lawitz Eric, Wyles David L, Bekele Neby, Brainard Diana, Symonds William T, McHutchison John G, Miller Michael D, Mo Hongmei

Abstract excerpt

BACKGROUND: Sofosbuvir is a chain-terminating nucleotide analogue inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase that is efficacious in subjects with HCV genotype 1-6 infection. Sofosbuvir resistance is primarily conferred by the S282T substitution in NS5B. METHODS: NS5B sequencing and susceptibility testing of HCV from subjects infected with genotypes 1-6 who participated in phase 2 and 3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Hepacivirus

Share to High-Throughput Nucleotide Sequencing

Share to Phenotype

Share to Sofosbuvir

Share to Treatment Outcome

Share to Uridine Monophosphate

Source

Open in PubMed Open full text

Identifiers

PMID: 25266287
DOI: 10.1093/cid/ciu697
PMCID: PMC6433438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.PMID 25266287Read ↗

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvirSemantic proximity Read ↗

In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.Semantic proximity Read ↗

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.Semantic proximity Read ↗

Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.Semantic proximity Read ↗

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.Semantic proximity Read ↗

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.Semantic proximity Read ↗

Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.Semantic proximity Read ↗

Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.Semantic proximity Read ↗

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.Semantic proximity Read ↗

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure.Semantic proximity Read ↗

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.Semantic proximity Read ↗

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.